ArticlePloS one2011
Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pooled it
- Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies.Oncotarget · 2017Pooled it
- rs833061 and rs699947 on promoter gene of vascular endothelial growth factor (VEGF) and associated lung cancer susceptibility and survival: a meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2014Pooled it
- Pooled it
- Mechanistic studies and therapeutic potential of angiopoietin in head and neck tumor angiogenesis.Frontiers in oncology · 2025Review
- The possible dual role of Ang-2 in the prognosis of pancreatic cancer.Scientific reports · 2023Article
- Article
- Update Overview of the Role of Angiopoietins in Lung Cancer.Medicina (Kaunas, Lithuania) · 2021Review
- Downregulation of ceramide synthase 1 promotes oral cancer through endoplasmic reticulum stress.International journal of oral science · 2021Article
- [Research Advances of Ang-2 in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- The expansion of targetable biomarkers for CAR T cell therapy.Journal of experimental & clinical cancer research : CR · 2018Review
- Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer.Scientific reports · 2018Article
- Article
- Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.World journal of surgical oncology · 2016Article
- Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer.Oncology letters · 2015Article
- Review
- Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].PloS one · 2014Article
- Expression and significance of angiopoietin-2 and cyclin D1 in laryngeal squamous cell carcinoma and the correlation with prognosis.Experimental and therapeutic medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAngiopoietins and their receptor Tie-2 are, in concert with VEGF-A, key mediators in angiogenesis. This study evaluates the prognostic impact of all known human angiopoietins (Ang-1, Ang-2 and Ang-4) and their receptor Tie-2, as well as their relation to the prognostic expression of VEGF-A.
methods335 unselected stage I-IIIA NSCLC-patients were included and tissue samples of respective tumor cells and stroma were collected in tissue microarrays (TMAs). Immunohistochemistry (IHC) was used to semiquantitatively evaluate the expression of markers in duplicate tumor and stroma cores. PRINCIPAL
findingsIn univariate analyses, low tumor cell expression of Ang-4 (P = 0.046) and low stromal expressions of Ang-4 (P = 0.009) and Ang-2 (P = 0.017) were individually associated with a poor survival. In the multivariate analysis, low stromal Ang-2 (HR 1.88; CI 95% 1.15-3.08) and Ang-4 (HR 1.47, CI 95% 1.02-2.11, P = 0.04) expressions were independently associated with a poor prognosis. In patients with high tumor cell expression of Ang-2, a concomitantly high tumor VEGF-A expression mediated a dramatic survival reduction (P<0.001). In the multivariate analysis of patients with high Ang-2 expression, high tumor VEGF-A expression appeared an independent poor prognosticator (HR 6.43; CI 95% 2.46-16.8; P<0.001).
conclusionsIn tumor cells, only Ang-4 expression has prognostic impact in NSCLC. In tumor stroma, Ang-4 and Ang-2 are independently associated with survival. The prognostic impact of tumor cell VEGF-A in NSCLC appears strongly associated with a concomitantly high tumor cell expression of Ang-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.